Welcome to
Breckenridge Pharmaceutical, Inc.

 

Breckenridge Pharmaceutical, Inc. is a Towa Company. 

 TOWA PHARMACEUTICAL CO.,LTD.

We are an own label distributor that performs pharmaceutical marketing, sales and distribution in the U.S.  The company was founded in 1983 and markets a broad range of generic prescription products in several therapeutic categories and dosage forms, including tablets, capsules, liquids, suspensions, ophthalmics, nasal sprays, powders, transdermal patches, and injectable products.

The Breckenridge label is recognized nationwide by wholesalers, distributors, chains, managed care accounts, and retail pharmacies.

Breckenridge, headquartered in Berlin, Connecticut, markets products under more than 40 Abbreviated New Drug Applications (ANDAs) approved by the Food and Drug Administration (FDA).                                    

 

 

Latest News

Zolpidem Tartrate Extended-Release Tablets, USP (generic for AmbienĀ® CR) launch

Jul 08,2021

Breckenridge Pharmaceutical, Inc. announced today that it has launched Zolpidem Tartrate Extended-Release Tablets, USP (generic for Ambien® CR), manufactured by Centaur Pharmaceuticals Pvt. Ltd.  Breckenridge will market the product in its own label and offer 6.25 mg and 12.5 mg strengths in bottles of 100. According to industry sales data, Ambien CR and its generics had annual sales of $42 million during the twelve months ending May 2021. The U.S. Food and Drug Administration previously granted final approval of this product’s Abbreviated New Drug Application. 

 

 

About Breckenridge:

Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. patients.  With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and quality of life of the patients we and our customers serve.

www.bpirx.com

 

About Centaur:

Centaur Pharmaceuticals is India’s 32nd largest pharmaceutical company by prescriptions. Centaur provides end to end pharmaceutical solutions and is India’s largest manufacturer and exporter of psychotropic API. Centaur exports its finished formulations to over 100 countries. Centaur recently introduced Woxheal, an NCE, for the first time in the world, in India for Diabetic Foot Ulcer.

www.centaurpharma.com

Read More >>

Multi-Product Agreement With Welding GmbH & Co, K.G.

Jul 02,2021

Breckenridge Pharmaceutical, Inc. announces today that it has signed a multi-product agreement with Welding GmbH & Co. under which Welding will develop, manufacture and supply pharmaceutical products for marketing, sale and distribution by Breckenridge.  The agreement currently covers one delayed release tablet product and two injectable products.  Of these three products, one ANDA has been submitted to the U.S. Food and Drug Administration, one ANDA is expected to be submitted to the U.S. Food and Drug Administration in July, and one ANDA is in an advanced stage of development.  According to industry sales data, the brand and generics of these three products had annual sales of $300 million during the twelve months ending April 2021.

 

 

About Breckenridge:

Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. patients.  With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and quality of life of the patients we and our customers serve.

www.bpirx.com

 

 

About Welding GmbH & Co, K.G.

Welding is a privately owned company, headquartered in Hamburg, Germany. Since foundation in 1955, Welding has built an excellent reputation as a service provider to the pharmaceutical industry by leading generic formulation projects from product development to regulatory procedures and routine supply. Welding has been involved in the procurement and distribution of drug substances, acquiring experience in regulatory affairs, quality systems and API project management in order to support manufacturers of finished dosage forms across the globe. Our success is built on experts with a proven track record in identifying and realizing product opportunities, enabling us to create substantial synergies between our global partners in Asia, Europe and the US.

www.welding.eu

Read More >>

Breckenridge Signs Multi-Product Agreement With Aggrega Pharma LLC

Jun 22,2021

Breckenridge Pharmaceutical, Inc. announces today that it has signed a multi-product agreement with Aggrega Pharma, LLC. under which Aggrega will develop, manufacture and supply pharmaceutical products for marketing, sale and distribution by Breckenridge.  The agreement currently covers eight products in a variety of dosage forms, including solid oral, nasal spray, ophthalmic, injectable and transdermal products. For these eight products, one ANDA has been approved, four ANDAs have been submitted to the U.S. Food and Drug Administration and three ANDAs are at advanced stages of development.  Breckenridge previously launched Succinylcholine Chloride Injection, USP, 20mg/mL under this agreement, which is now available from Breckenridge as a carton of 25 vials.   According to industry sales data, these eight products and their generics had annual sales of $500 million during the twelve months ending April 2021.

 

 

About Breckenridge:

Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Pharmaceutical (Osaka, Japan), partners with manufacturers nationwide and around the world to bring quality, cost-effective generic pharmaceuticals to U.S. patients.  With our dedication to customer service, on-time delivery, reliable supply and quality manufacturing, we improve the health and quality of life of the patients we and our customers serve.

www.bpirx.com

 

 

About Aggrega Pharma, LLC:

Aggrega Pharma, LLC. is a first-class pharmaceutical company developing, manufacturing and marketing generic medications (injectable, ophthalmic, oral and topical finished dosage forms). The shareholders are 4 European companies:  Bluepharma, Rafarm, Substipharm and Welding. Aggrega Pharma is committed to building a pipeline of complex and selected generic products by leveraging the vast R&D, clinical and manufacturing experience and capabilities of its members. Our portfolio includes products that are commercialized as well as products to be launched soon.

www.aggregapharma.com

Read More >>

Product Search

All brand names are registered trademarks of their respective owner(s).